TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Condition(s):HER2-positive Breast Cancer; Brain MetastasesLast Updated:June 2, 2021Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):HER2-positive Breast Cancer; Brain MetastasesLast Updated:June 2, 2021Not yet recruiting
Condition(s):The Primary Study Metric is Progression-free Survival (PFS)Last Updated:July 7, 2023Completed
Condition(s):Non-small Cell Lung Cancer (NSCLC); EGFR-TKI Resistant Mutation; EGFR-TKI Sensitizing Mutation; Germline Mutations; Somatic MutationLast Updated:April 12, 2023Recruiting
Condition(s):Folate; CML; Treatment-free RemissionLast Updated:January 3, 2022Unknown status
Condition(s):Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; EGFR T790MLast Updated:July 23, 2020Unknown status
Condition(s):SafetyLast Updated:March 8, 2021Unknown status
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:April 26, 2018Completed
Condition(s):Non-small Cell Lung Cancer Stage III; Non-Small-Cell Lung Cancer MetastaticLast Updated:March 12, 2018Completed
Condition(s):Clear-cell Metastatic Renal Cell CarcinomaLast Updated:November 14, 2018Terminated
Condition(s):Lung Diseases; Neoplasms; Respiratory Tract Diseases; Thoracic Neoplasms; Non-Small-Cell LungLast Updated:January 3, 2018Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.